Sinha, A.; Zou, Y.; Patel, A.S.; Yoo, S.; Jiang, F.; Sato, T.; Kong, R.; Watanabe, H.; Zhu, J.; Massion, P.P.;
et al. Early-Stage Lung Adenocarcinoma MDM2 Genomic Amplification Predicts Clinical Outcome and Response to Targeted Therapy. Cancers 2022, 14, 708.
https://doi.org/10.3390/cancers14030708
AMA Style
Sinha A, Zou Y, Patel AS, Yoo S, Jiang F, Sato T, Kong R, Watanabe H, Zhu J, Massion PP,
et al. Early-Stage Lung Adenocarcinoma MDM2 Genomic Amplification Predicts Clinical Outcome and Response to Targeted Therapy. Cancers. 2022; 14(3):708.
https://doi.org/10.3390/cancers14030708
Chicago/Turabian Style
Sinha, Abhilasha, Yong Zou, Ayushi S. Patel, Seungyeul Yoo, Feng Jiang, Takashi Sato, Ranran Kong, Hideo Watanabe, Jun Zhu, Pierre P. Massion,
and et al. 2022. "Early-Stage Lung Adenocarcinoma MDM2 Genomic Amplification Predicts Clinical Outcome and Response to Targeted Therapy" Cancers 14, no. 3: 708.
https://doi.org/10.3390/cancers14030708
APA Style
Sinha, A., Zou, Y., Patel, A. S., Yoo, S., Jiang, F., Sato, T., Kong, R., Watanabe, H., Zhu, J., Massion, P. P., Borczuk, A. C., & Powell, C. A.
(2022). Early-Stage Lung Adenocarcinoma MDM2 Genomic Amplification Predicts Clinical Outcome and Response to Targeted Therapy. Cancers, 14(3), 708.
https://doi.org/10.3390/cancers14030708